Hosted on MSN2mon
Mersana falls after early-stage trial data for lead cancer therapyCancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
As part of Une Jonquille contre le Cancer 2025, which takes place across France from March 11 to 23, pastry chef Jessica ...
9d
News Medical on MSNTransplantation combined with immunotherapy to cure liver cancerA study led by the UNIGE and the HUG shows that an interval of at least 50 days between stopping immunotherapy and liver transplantation significantly reduces the risk of rejection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results